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Abstract
We recently demonstrated that removal of one kidney (uninephrectomy; UniNx) in 
mice reduced high fat-diet (HFD)-induced adipose tissue inflammation thereby improving 
adipose tissue and hepatic insulin sensitivity. Of note, circulating cystatin C (CysC) levels 
were increased in UniNx compared to sham-operated mice. Importantly, CysC may have 
anti-inflammatory properties, and circulating CysC levels were reported to positively 
correlate with obesity in humans and as shown herein in HFD-fed mice. However, the 
causal relationship of such observation remains unclear. HFD feeding of CysC-deficient 
(CysC KO) mice deteriorated obesity-associated adipose tissue inflammation and 
dysfunction, as assessed by pro-inflammatory macrophage accumulation. In addition, 
mRNA expression of pro-inflammatory mediators was increased, whereas markers of 
adipocyte differentiation were decreased. Similarly to findings in adipose tissue, 
expression of pro-inflammatory cytokines was increased in liver and skeletal muscle of 
CysC KO mice. In line, HFD-induced hepatic insulin resistance and impairment of glucose 
tolerance were further aggravated in knockout mice. Consistently, chow-fed CysC KO 
mice were more susceptible to lipopolysaccharide (LPS)-induced adipose tissue 
inflammation. In people with obesity, circulating CysC levels correlated negatively with 
adipose tissue Hif1α as well as IL-6 mRNA expression. Moreover, healthy (i.e. insulin-
sensitive) subjects with obesity depicted significantly higher mRNA expression of CysC in 
white adipose tissue.
In conclusion, CysC is upregulated under obesity conditions and thereby 
counteracts inflammation of peripheral insulin-sensitive tissues and, thus, obesity-
associated deterioration of glucose metabolism.
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Introduction
Obesity-induced inflammation is a crucial driver of insulin resistance and type 2 
diabetes. In obesity, white adipose tissue (WAT) expansion is associated with local 
infiltration of pro-inflammatory cells, with macrophages being the quantitatively 
predominant cell type. The latter accounts for a large proportion of adipose tissue-derived 
pro-inflammatory proteins such as IL-1β, IL-6, TNFα or hypoxia-inducible factor-1α 
(HIF1α) (1), altering the secretory pattern of adipocytes. Consequently, the release of pro-
inflammatory cytokines and free fatty acids (FFA) is increased contributing to the vicious 
circle of obesity-associated chronic low grade inflammation locally as well as systemically, 
e.g. in the liver and in skeletal muscle (2, 3). Due to the central role of inflammation in the 
pathogenesis of type 2 diabetes, identification of anti-inflammatory targets to combat 
insulin resistance and its related co-morbidities are warranted (4).
We previously found that removal of one kidney (uninephrectomy; UniNx) in obese 
mice ameliorates obesity-induced adipose tissue and liver inflammation (5, 6). Cystatin C 
(CysC) is a marker of the glomerular filtration rate (7) and increased in patients with renal 
failure (8). Since CysC was previously reported to have immunomodulatory function, we 
hypothesized that increased circulating CysC levels contributed to the blunted 
inflammation in UniNx mice. CysC was found to be internalized into lipopolysaccharide 
(LPS)-stimulated monocytes and to downregulate the production of pro-inflammatory 
cytokines such as TNFα or IL-1β (9). Moreover, an association between elevated 
circulating CysC levels and type 2 diabetes has been reported (10, 11). However, the 
pathophysiological implication of such association remains to be elucidated. Herein, we 
propose that elevated CysC levels in obesity counterbalance obesity-associated 
inflammation thereby restoring glucose tolerance. 
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Research Design and Methods
Human Studies
Serum concentration of CysC, IL-10 and lipocalin-2 as well as mRNA expression 
in subcutaneous or visceral WAT were determined in 63 individuals (age 19-82 years; BMI 
25-75 kg/m²) who underwent laparoscopic sleeve gastrectomy, cholecystectomy, hernia 
or Roux-en-Y gastric bypass surgery. In addition, CysC mRNA expression in 
subcutaneous WAT was analyzed in a previously described subgroup of individuals with 
either insulin-sensitive (n=30) or insulin-resistant obesity (n=30) (12). All investigations 
were approved by the ethics committee of the University of Leipzig (# 159-12-21052012) 
and were carried out in accordance with the Declaration of Helsinki. All participants 
provided witnessed written informed consent before study entrance. mRNA expression 
was measured by qRT-PCR using Assay-on-Demand gene expression kit and calculated 
relative to the expression of HPRT1 mRNA. For primer details see Supplementary Tab. 
1.
Animals
CysC-deficient mice (13) were bred to C57BL/6J wildtype mice to eventually obtain 
homozygous CysC KO and (wild-type) WT littermates. 
Mice were housed in a pathogen-free environment with an alternating 12 h dark 
and light cycle. Six-week old male WT and CysC KO mice were fed ad libitum either a 
regular chow (ProvimiKliba) or a HFD (59 kcal% fat, D12331 mod. Surwit, ssniff 
Spezialdiäten GmbH, for 20 weeks. All protocols conformed to the Swiss animal protection 
laws and were authorized by the Cantonal Veterinary Office in Zurich, Switzerland.
Page 4 of 40Diabetes
5
Intraperitoneal glucose and insulin tolerance tests
Glucose and insulin tolerance were assessed as described (14).
Hyperinsulinemic-euglycemic clamp studies 
Hyperinsulinemic-euglycemic clamp studies were performed as described before 
(15).
Metabolic cage analysis
Energy expenditure, locomotor activity and food intake were assessed in 24-hour 
single-housed mice using the PhenoMaster system (TSE Systems). 
Determination of plasma parameters
Free fatty acid (FFA) concentrations were determined using an enzymatic 
colorimetric assay (Wako Chemicals GmbH). Plasma CysC (BioVendor) and insulin 
(Crystal Chem) levels were measured using ELISA kits.
Adipocyte size determination
Distribution of adipocyte diameter was determined by the MultisizerTM 3 Coulter 
Counter (Beckman Coulter Life Sciences). 
Real time quantitative PCR
cDNA was amplified using TaqMan assays (Applied Biosystems) and normalized 
to 18s RNA using the 2-∆∆CT method. For primer details see Supplementary Tab. 2.
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Western Blotting
Western blots were obtained as described (14). For antibody details see 
Supplementary Tab. 3.
Flow cytometry
Stromal-vascular fraction of eWAT was collected as described (16). For staining 
details see Supplementary Tab. 4. Measurements were performed with a flow cytometer 
(Beckman Coulter), and data were analyzed with FlowJo software. Relative frequency of 
single, live lymphocytes of the respective subpopulation was assessed. 
Osmotic mini-pump experiments
Osmotic mini-pump (Alzet Model 1004) was implanted into the intraperitoneal 
cavity of anesthetized 12-week old mice. Mini-pumps were filled with LPS from 
Escherichia coli (055:B5, Sigma) to infuse 300 µg/kg*day for four weeks. 
Data analysis
Data were analyzed by Spearman correlation, unpaired, two-tailed Student’s t-test 
or by one- or two-way analysis of variance (ANOVA) followed by Bonferroni post-hoc test. 
Data and Resource Availability
All data generated or analyzed during this study are included here (and in 
Supplementary Data) or are available from the corresponding author upon reasonable 
request.
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Results
Higher degree of adiposity in HFD-fed CysC KO mice
First, we explored the effect of HFD-feeding on circulating CysC levels in WT mice. 
As depicted in Fig. 1A, 20 weeks of HFD increased plasma CysC concentrations in 
systemic and portal (Supplementary Fig. 1A) blood compared to age-matched chow-fed 
mice independently of kidney function since plasma creatinine levels were similar among 
chow- and HFD-fed WT mice (Supplementary Fig. 1B). Moreover, CysC plasma levels 
were significantly increased in HFD-fed UniNx compared to sham-operated mice (Fig. 
1B). Of note, UniNx had a protective effect on HFD-induced adipose tissue inflammation 
and hepatic insulin resistance (5). To explore a potential role of increased CysC on 
adipose tissue function, we analyzed CysC KO mice (13). As expected, CysC was absent 
in the circulation of CysC KO mice (Fig. 1C). CysC KO mice exhibited lower body weight 
under chow-diet whereas it was no longer different in HFD-fed mice (Fig. 1D). 
Furthermore, mass of inguinal and mesenteric fat depots was significantly increased in 
HFD-fed knockout mice (Fig. 1E). Such increased fat accumulation might be due to a 
pronounced positive energy balance since we observed diminished locomotor activity and 
decreased energy expenditure in HFD-fed CysC KO mice that may have outweighed 
lower food intake in these mice (Supplementary Fig. 2). Of note, whereas energy 
expenditure was similarly decreased in chow-fed CysC KO mice, their locomotor activity 
and food intake were not different when compared to WT mice (Supplementary Fig. 3).
In inguinal WAT (iWAT) of HFD-fed mice, levels of the adipocyte differentiation 
markers PPARγ and CEBPβ were decreased (Figs. 1F and G). Consistently, adipocyte 
size was enlarged in HFD-fed CysC KO mice (Fig. 1H). In contrast, PPARγ and CEBPβ 
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protein levels were similar in iWAT of chow-fed WT and CysC KO mice (Supplementary 
Fig. 4A). Moreover, recombinant CysC treatment did not affect differentiation of 3T3-L1 
adipocytes (Supplementary Fig. 4B), indicating that CysC has no direct effect on the latter. 
Obesity-associated adipose tissue dysfunction is accompanied by impaired angiogenesis 
(17). In accordance, levels of the pro-angiogenic protein vascular endothelial growth factor 
(VEGF) were decreased in iWAT of HFD-fed CysC KO mice (Supplementary Fig. 5A). 
Similarly, VEGF protein levels were decreased in skeletal muscle (Supplementary Fig. 
5B). Taken together, lack of CysC aggravates HFD-induced adiposity and reduces 
adipocyte differentiation markers consistent with adipose tissue dysfunction in these mice.
Pronounced obesity-induced impairment of glucose metabolism in CysC KO mice 
Glucose metabolism was assessed next in chow- and HFD-fed CysC KO and WT 
mice. Whereas CysC KO mice were slightly more glucose tolerant under chow diet, 
glucose tolerance was further deteriorated in HFD-fed CysC KO compared to WT mice 
(Figs. 2A-C). Accordingly, the negative impact of HFD on glucose tolerance was 
significantly more pronounced in CysC KO mice (Fig. 2D). Insulin tolerance was increased 
in chow-fed but similar in HFD-fed CysC KO mice when compared to WT mice 
(Supplementary Figs. 6A-D). Circulating insulin levels were similar in both genotypes 
under both diets (Supplementary Fig. 6E). Hyperinsulinemic-euglycemic clamp studies 
revealed similar glucose infusion rate reflecting similar whole-body insulin sensitivity in 
HFD-fed CysC KO and WT mice (Fig. 2E). In contrast, endogenous glucose production 
was significantly higher in CysC KO mice (Fig. 2F) indicating impaired hepatic insulin 
sensitivity. Whereas glucose uptake into white adipose tissue depots was comparable 
between both genotypes, glucose uptake into glycolytic soleus muscle was trend-wise 
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increased in CysC KO mice (Fig. 2G). Possibly, this increased glucose uptake into soleus 
counteracted blunted insulin response in the liver, resulting in an overall similar glucose 
infusion rate (Fig. 2E). Albeit not significantly different, glucose uptake into iWAT was 
almost 50% lower in CysC KO (Fig. 2G). In addition, insulin’s capacity to reduce circulating 
FFA during clamps was significantly blunted in CysC KO mice (Fig. 2H), suggesting 
impaired WAT insulin sensitivity. Taken together, CysC KO mice are more susceptible to 
HFD-induced deterioration of glucose tolerance.
Increased expression of pro-inflammatory cytokines in WAT of HFD-fed and LPS-treated 
chow-fed CysC KO mice
CysC may have anti-inflammatory properties (9). Consistently, mRNA expression 
of pro-inflammatory proteins was increased in both iWAT as well as epididymal WAT 
(eWAT) of HFD-fed CysC KO mice (Figs. 3A and B). In line, infiltration with pro-
inflammatory macrophages was enhanced in eWAT of HFD-fed CysC KO compared to 
WT mice as assessed by flow cytometry (Fig. 3C and Supplementary Fig. 7). Similar to 
WAT, expression of pro-inflammatory cytokines was increased in liver and skeletal muscle 
of HFD-fed CysC KO mice (Figs. 3D and E). In contrast, mRNA expression of these 
cytokines was not different between both genotypes under chow diet (Supplementary Fig. 
8). 
To explore whether chow-fed CysC KO mice were more susceptible to exogenous 
pro-inflammatory stimuli, LPS, which was demonstrated to promote adipose tissue 
inflammation in lean mice (18), was chronically administrated to chow-fed CysC KO and 
WT mice using mini-pumps. We hypothesized that an isolated increase in circulating LPS 
levels would aggravate adipose tissue inflammation in chow-fed mice lacking the 
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protective effect of CysC. Indeed, adipose tissue inflammation was pronounced in lean 
CysC KO mice, as demonstrated by increased mRNA expression of IL-6 (Fig. 3F). In line, 
phosphorylation of IL-6 downstream targets such as STAT3 and ERK 1/2 were increased 
in CysC KO mice (Supplementary Fig. 9). 
CysC can be internalized into LPS-stimulated macrophages thereby 
downregulating the expression and secretion of pro-inflammatory cytokines (9, 19). CysC-
treatment of LPS-stimulated RAW cells decreased mRNA expression of Hif1α (Fig. 3G), 
which has been previously linked to adipose tissue inflammation (20). In parallel, the 
release of TNFα and MCP1 was reduced (Supplementary Fig. 10). To test potential anti-
inflammatory properties of CysC in obesity-associated adipose tissue inflammation, 
eWAT explants of HFD-fed mice were incubated with or without recombinant CysC. 
Importantly, CysC-treatment significantly reduced Hif1α mRNA levels in eWAT explants 
(Fig. 3H). In addition, Vegf-A mRNA expression was upregulated in response to CysC-
treatment (Supplementary Fig. 11). 
Taken together, CysC modulates inflammation in insulin-sensitive tissues in mice. 
Negative correlation of circulating CysC levels with inflammation markers in human WAT
Consistent to observation in rodents (Fig. 3A), circulating CysC levels correlated 
negatively with HIF1α (Fig. 4A) and TNFα (Fig. 4B) mRNA expression in subcutaneous 
white adipose tissue of human subjects. Similarly, HIF1α and IL-6 mRNA expression in 
visceral WAT associated negatively with serum CysC concentration (Figs. 4C and D). 
Moreover, the latter correlated negatively with the pro-inflammatory protein lipocalin-2 
(Fig. 4E), but positively with the anti-inflammatory cytokine IL-10 (Fig. 4F). In further 
support of anti-inflammatory properties of CysC, healthy i.e. insulin-sensitive obese 
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subjects depicted higher CysC mRNA expression in subcutaneous WAT than insulin-
resistant obese patients (Fig. 4G).   
Discussion
The current study shows that elevated circulating CysC levels in obesity reduce 
(adipose) tissue inflammation and, thus, has a beneficial impact on glucose tolerance. 
Circulating CysC is not only increased in kidney failure, but also in obese humans and 
mice (21, 22). Consistently, we found increased circulating CysC levels in 
uninephrectomized as well as in HFD-fed mice. Of note, WAT from obese humans 
revealed higher expression and secretion of CysC, suggesting a direct contribution of 
WAT to obesity-associated increase in circulating CysC (23). Similarly, murine WAT 
expresses significant amounts of CysC (24), supporting the notion that WAT is as an 
important source of circulating CysC levels. 
In support of the suggested anti-inflammatory properties of CysC, its circulating 
levels correlated negatively with inflammatory markers in human subcutaneous and 
visceral WAT and, additionally, CysC-treatment reduced inflammatory markers in murine 
fat explants. Moreover, lack of CysC promotes an aggravation of HFD-induced WAT, liver 
and skeletal muscle inflammation in mice as determined by mRNA expression of pro-
inflammatory cytokines and accumulation of pro-inflammatory macrophages in WAT. A 
putative role of obesity-associated macrophage accumulation as a major cytokine source 
and, hence, as driver of WAT inflammation has been suggested before (1). CysC may 
inhibit secretion of pro-inflammatory cytokines by LPS-stimulated macrophages (9). 
Consistently, we found herein that LPS-mediated WAT inflammation was aggravated in 
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lean CysC-deficient mice, suggesting a direct immunomodulatory effect of CysC on WAT 
inflammation. In the latter experiment, chronically LPS-treated CysC KO mice displayed 
not only pronounced IL-6 upregulation but also increased activation of its downstream 
targets STAT3 and ERK 1/2 when compared to WT mice. Of note, a regulatory effect of 
CysC on LPS-stimulated ERK 1/2-phosphorylation has been reported in human 
monocytes before (9). 
Obesity-associated WAT inflammation may inhibit adipogenesis resulting in 
adipocyte hypertrophy (17, 20). In fact, inflammatory mediators such as IL-6 and TNFα 
that are both elevated in WAT of HFD-fed KO mice may negatively affect adipocyte 
differentiation and/or induce de-differentiation of white adipocytes (25, 26). In support of 
such notion, elevated Il-6 and Tnfα expression observed in HFD-fed CysC-deficient mice 
was associated with diminished protein levels of the adipocyte differentiation factors 
PPARγ and CEBPβ as well as hypertrophied adipocytes further supporting our hypothesis 
that CysC elicits anti-inflammatory properties and, thus, may counteract WAT 
inflammation. Moreover, we observed decreased levels of the pro-angiogenic protein 
VEGF-A, which is important for healthy WAT expansion and vascularization (17), in WAT 
of HFD-fed CysC KO mice. Consistently, CysC has been reported to increase VEGF (27). 
These findings further support a beneficial role of CysC in adipose tissue of obese.
In conclusion, increased CysC in obesity may counterbalance obesity-associated 
inflammation and, thus, protects from additional obesity-associated deterioration of 
glucose homeostasis. Besides elevated inflammation, increased HFD-induced body 
weight gain and/or impaired vascularization may contribute to impaired glucose tolerance 
in HFD-fed Cys C KO mice.
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Figure Legends
Fig. 1 Higher degree of adiposity in HFD-fed CysC KO mice
(A) Plasma levels of CysC in systemic blood of WT mice (n=23 chow-fed mice and n=12 
HFD-fed mice). (B) Plasma levels of CysC in systemic blood of HFD-fed UniNx and sham-
operated mice (n=6 mice per group). (C) Circulating CysC levels of WT and CysC KO 
mice (n=4 WT and n=3 CysC KO mice). (D) Weight gain curves of WT and CysC KO mice 
over 20 weeks of chow- or HFD-feeding (n=35 chow-fed WT and n=29 chow-fed CysC 
KO, n=25 HFD-fed WT and n=23 HFD-fed CysC KO) are depicted. (E) Weight of white 
adipose tissue depots of HFD-fed WT and CysC KO mice (n=9 mice per group). 
Representative Western blots and quantification of protein levels of PPARγ (F) and 
CEBPβ (G) in iWAT (n=4 WT and n=5 CysC KO). Protein levels were normalized to WT 
mice. (H) Adipocyte size distribution within iWAT of HFD-fed WT and CysC KO mice. 
Shown are representative pictures of H&E-stained histological sections (scale bar=100 
μm) as well as the proportional distribution of different adipocyte size (n=5 WT and n=3 
CysC KO). Values are expressed as mean (H) or mean±SEM (A-G). #p=0.09, *p<0.05, 
**p<0.01. Two-way ANOVA (D), Student’s t-test (A, B, E-G). 
Fig. 2 Pronounced obesity-induced impairment of glucose metabolism in CysC 
KO mice
(A-C) Intraperitoneal glucose tolerance test (ipGTT) of chow- (n=20 WT and n=19 CysC 
KO mice) and HFD-fed (n=16 WT and n=12 CysC KO mice) WT and CysC KO mice. (D) 
HFD-induced increase of area under the curve (AUC) relative to corresponding chow-fed 
baseline level (n=16 WT and n=12 CysC KO mice). Glucose infusion rate (GIR) (E), 
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endogenouse glucose production (EGP) (F) and tissue glucose uptake (G) during 
hyperinsulinemic-euglycemic clamp (n=4 WT and n=5-6 CysC KO mice). (H) Insulin–
mediated reduction in circulating FFA levels during hyperinsulinemic-euglycemic clamp 
(n=3 mice per group). Values are expressed as mean±SEM. #p=0.1, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. Student’s t-test (D-H), two-way ANOVA (A, B), one-way 
ANOVA (C).
Fig. 3 Increased expression of pro-inflammatory cytokines in WAT of HFD-fed and 
LPS-treated chow-fed CysC KO mice
mRNA expression of pro-inflammatory markers in iWAT (A; n=7-8 WT and n=6-7 CysC 
KO mice) and eWAT (B; n=5 WT and n=6-7 CysC KO) of HFD-fed WT and CysC KO 
mice. (C) Numbers of CD11b+ F4/80+ Ly6G- Ly-6Chigh macrophages relative to live, single 
lymphocytes after excluding neutrophils and eosinophils in the stromal vascular fraction 
of eWAT obtained from HFD-fed WT and CysC KO mice (n= 4 mice per group, 2 
independent experiments). mRNA expression of pro-inflammatory cytokines in liver (D; 
n=5 WT and n=4 CysC KO) and in skeletal muscle (E; n=5 WT and n=6-7 CysC KO) of 
HFD-fed CysC KO mice are depicted. (F) mRNA expression of pro-inflammatory 
mediators in eWAT of LPS-infused chow-fed WT and CysC KO mice (n=6 mice per group). 
(G) mRNA expression of Hif1α in LPS-stimulated RAW 264.7 cells in the absence or 
presence of CysC (n=6 independent experiments). (H) mRNA expression of Hif1α in 
eWAT explants harvested from HFD-fed mice and treated with or without recombinant 
CysC (n=5 independent experiments). Values are expressed as mean±SEM. #p=0.06 (A), 
#p=0.09 (B), *p<0.05, **p<0.01, ***p<0.001. Student’s t-test.
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Fig. 4 Negative correlation of circulating CysC levels with inflammation markers 
in human WAT
Scatter plot and correlation coefficient (r) of log circulating CysC concentration and 
subcutaneous WAT HIF1α (A), subcutaneous WAT TNFα (B), visceral WAT HIF1α (C) 
and visceral WAT IL-6 (D) mRNA expression (n=62-63). Scatter plot and correlation 
coefficient (r) of log circulating CysC concentration and serum lipocalin-2 (E) or serum IL-
10 (F) concentration (n=42-44). (G) CysC mRNA expression in subcutaneous WAT of 
insulin-sensitive and insulin-resistant healthy obese patients (n=30 patients per group). 
*p<0.05, (Student’s t-test).
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Obesity-Induced Increase in Cystatin C Alleviates Tissue Inflammation 
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Supplementary Figure 1 
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Increased circulating cystatin C levels in HFD-fed mice 
(A) Plasma levels of cystatin C in portal blood of WT mice (n=4 chow-fed mice and n=3 
HFD-fed mice). (B) Plasma levels of creatinine in systemic blood of chow- and HFD-
fed WT mice (n=11 chow-fed mice and n=6 HFD-fed mice). Values are expressed 
mean±SEM. *p<0.05 (Student’s t-test). 
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Decreased locomotor activity, energy expenditure and food intake in HFD-fed 
CysC KO mice 
(A) Locomotor activity, (B) energy expenditure and (C) food intake of HFD-fed WT and 
CysC KO mice (n=7 WT and n=6 CysC KO mice). Values are expressed as 
mean±SEM. (A) #p=0.06. *p<0.05 (Student’s t-test). 
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Similar locomotor activity and food intake, but decreased energy expenditure in 
chow-fed CysC KO mice 
(A) Locomotor activity, (B) energy expenditure and (C) food intake of chow-fed WT and 
CysC KO mice (n=6 WT and n=7 CysC KO mice). Values are expressed as 
mean±SEM. #p=0.06, *p<0.05 (Student’s t-test). 
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Diff. mix (w/o rosiglitazone) 
Rosiglitazone 
Cystatin C (µg/ml) 
+ + + + + + - 
- - - - - + - 
- 0.1 0.5 1 2 - - 
Diff. mix (w/o rosiglitazone) 
Rosiglitazone 
Cystatin C (µg/ml) 
+ + + + + + - 
- - - - - + - 
- 0.1 0.5 1 2 - - 
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No effect of recombinant CysC on 3T3-L1 adipocyte differentiation 
(A) Quantification of protein levels of PPARγ and CEBPβ in iWAT of chow-fed WT 
(n=4) and CysC KO (n=5). Protein levels were normalized to WT mice. (B) Confluent 
3T3-L1 adipocytes were treated for three days with or without a differentiation (Diff.) 
mix containing 500 µM isobutylmethylxanthine, 1 µM dexamethasone and 1.7 µM 
insulin, rosiglizatone (1µM) and different concentrations of recombinant CysC as 
indicated. Thereafter, cells were treated for three days with or without a second Diff. 
mix containing 0.5 µM insulin and different concentrations of recombinant CysC as 
indicated. Six days after induction of differentiation, cells were lysed and Western blots 
were performed. Shown are quantified protein levels of PPARу and CEBPβ. n=4 
biological replicates. Values are expressed as mean±SEM. *p<0.05, ***p<0.001 
(ANOVA, compared to undifferentiated cells). 
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Decreased VEGF levels in skeletal muscle of HFD-fed CysC KO mice  
Representative Western blots and quantification of protein levels of VEGF in iWAT (A; 
n=4 WT and n=5 CysC KO) and in skeletal muscle of HFD-fed mice (B; n=5 mice per 
group). Protein levels were normalized to WT mice. Values are expressed as 
mean±SEM. *p<0.05 (Student’s t-test). 
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Supplementary Figure 6 
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Insulin tolerance in chow- and HFD-fed WT and CysC KO mice  
Intraperitoneal insulin tolerance test (ipITT) in chow- (n=18 WT and n=15 CysC KO 
mice) and HFD-fed (n=11 WT and n=18 CysC KO mice) WT and CysC KO mice (A-
D). (E) Circulating insulin levels of chow- and HFD-fed WT mice (chow n=5, HFD n=4) 
as well as CysC KO mice (chow n=4, HFD=5). Values are expressed as mean±SEM. 
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Gating strategy on cells in eWAT 
Lymphocytes and single cells were initially identified by size. PI negative cells were 
identified as alive. Following exclusion of Eosinophils we gated on F4/80. Afterwards 
Ly6G negative cells were gated on macrophages based on CD11b and Ly6C 





































































































Page 32 of 40Diabetes




































































































Similar expression of pro-inflammatory cytokines in WAT of chow-fed WT and 
CysC KO mice 
mRNA expression levels of pro-inflammatory cytokines in (A) eWAT (n= 5 mice per 
group), (B) Liver (n=3 per group) and (C) skeletal muscle (n=6 per group) of chow-fed 
WT and CysC KO. Values are expressed as mean±SEM. 
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Increased ERK and STAT3 phosphorylation in adipose tissue of LPS-treated 
CysC KO mice 
Phosphorylation levels of selected IL-6 downstream targets ERK 1/2 (A) and STAT3 
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Decreased release of pro-inflammatory mediators from CysC-treated RAW cells 
MCP1, TNFα and IL-6 protein levels were determined in the supernatant of LPS-
stimulated RAW 264.7 cells in the absence (controls (Co), black bars) or presence of 
CysC (grey bars). Protein release was normalized to RNA concentration and is shown 
relative to Co cells. n=4 independent experiments. #p<0.1, *p<0.05 (One sample t-test). 
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Increased Vegf-A expression in cystatin C-treated eWAT explants 
mRNA expression of Vegf-A in eWAT explants harvested from HFD-fed mice and 
treated with or without recombinant cystatin C (n=5 independent experiments). Values 
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Supplementary Tab. 1 mRNA primer used for experiments in human 
individuals  
 





HPRT1 mRNA Hs01003267_m1 
 
Primers were provided by Applied Biosystems, Darmstadt, Germany 
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Supplementary Tab. 2 mRNA primer used for experiments in mice  
 






Primers were provided by Applied Biosystems, Rotkreuz, Switzerland 
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Supplementary Tab. 3 Order number of primary antibodies used 
 
Target Order number Company 
Actin MAB1501 Millipore, Billerica, MA, USA 
CEBPβ sc-150 Santa Cruz Biotechnology, Dallas, TX, USA 
PPARγ sc-7196 Santa Cruz Biotechnology 
pSTAT3 (Tyr705) D3A7 Santa Cruz Biotechnology 
VEGF sc-7269 Santa Cruz Biotechnology 




9101 Cell Signaling Technology 
GAPDH 10494-1-AP Proteintech, Rosemont, IL, USA 
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PE–anti-Ly6G BioLegend Way 
APC-Cy7–anti-Ly6C (clone HK1.4) BioLegend Way 
Biotin–anti-Siglec-F BioLegend Way 
Alexa Fluor 700–streptavidin BioLegend Way 
APC–anti-F4/80 BioLegend Way 
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